|
Orthologous residues
|
|
Bcl‑2 (human): S70‑p, Bcl‑2 (mouse): S70‑p, Bcl‑2 (rat): S70‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site
|
|
Disease tissue studied:
leukemia
|
|
Relevant cell lines - cell types - tissues:
FDCP-1 (myeloid), NSF/N1.H7 (myeloid)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
JNK1 (human)
|
pharmacological activator of upstream enzyme, transfection of dominant-negative enzyme, microscopy-colocalization
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
anisomycin
|
|
|
|
increase
|
|
|
okadaic acid
|
|
|
|
increase
|
|
|
okadaic acid
|
okadaic acid
|
|
|
inhibit treatment-induced increase
|
|
|
IL-3
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
apoptosis, inhibited
|
